The Development of Cannabidiol as a Psychiatric Therapeutic: A Review of Its Antipsychotic Efficacy and Possible Underlying Pharmacodynamic Mechanisms
Shahin AM Jalali, William E. Johnson
International Neuropsychiatric Disease Journal · pp. 113–147 · Published 11 Oct 2013
10.9734/INDJ/2013/6192Abstract
Cannabidiol (CBD), a once-considered inert cannabis constituent, is one of two primary constituents of cannabis, alongside delta-9-tetrahydrocannabinol (∆9-THC/THC). In the last 30 years, CBD has become implicated with a range of pharmaceutical mechanisms of great therapeutic interest and utility. This review details the literature speculating CBD’s attenuation of psychotic symptoms, particularly in light of a marked elevation in mean THC concentrations, and a concomitant decline in CBD concentrations in the prevalent U.K street market cannabis derivatives since c. 2000. CBD is purported to exhibit pharmacology akin to established atypical antipsychotics, whilst THC has been implicated with the precipitation of psychosis, and the induction of associated symptoms. The aim of the review was to clarify the conjecture surrounding CBD’s antipsychotic efficacy, before going on to detail prominent theories about its associated pharmacodynamics. Were CBD’s antipsychotic efficacy established, then there is potential for major latent anthropological repercussions to manifest, such as significant elevations in psychosis manifestations in the U.K. The review found a largely affirmative body of evidence asserting CBD’s antipsychotic efficacy. CBD exhibited capacity to attenuate natural and artificially induced psychoses in both animal and human cohorts, the latter of which included individuals considered resistant to conventional treatment. CBD also shows promising potential for use as an antipsychotic drug for Parkinson’s disease (PD) patients with psychosis, owing to its low rate of extra-pyramidal side-effect induction. A range of potential pharmacological mechanisms behind CBD’s neuroleptic pharmacology are outlined, with particular emphasis on its prevention of the hydrolysis and reuptake of the endogenous cannabinoid, anandamide. However, given the nebular aetiological basis for psychoses, explicit conclusions on how CBD attenuates psychotic symptoms remains to be determined.
Cited by 2
Scott D. Lane, Lokesh R. Shahani, Rodrigo Machado-Vieira · Psychiatry Research Communications · 2024
Robert-Alexandru Vlad, Lenard Farczadi, Silvia Imre · Acta Medica Marisiensis · 2019
Related research
- Low Prevalence of Metabolic Syndrome in a Group of Patients with Chronic Psychotic Disorders Taking Antipsychotic Polypharmacy in Residential Treatment While Adhering to a Mediterranean Diet — shares topic coverage
- Clinical Motivation Experience Practicum at Rehabilitation Center, Boston: A Case Study — shares topic coverage
- Review of the Challenges Facing Management of Patients with Psychotic Disorder and the Need for Mental Health Policies in Nigeria — shares topic coverage
- Perceived Barriers to Help Seeking for Psychosis among Secondary School Students in Lagos, Nigeria — shares topic coverage
- Periodic Catatonia after Thyroid Cancer — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
2
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.